Recent Updates
Recently added Catalysts

MK0822A

Phase 2

Vitamin D Deficiency | Small molecule | Other |Merck & Company, Inc.|Last Updated: May 14, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment216
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00242476A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)PHASE2 COMPLETED 216Sep 1, 2005Jul 1, 2006May 14, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mediolateral body sway at 16 weeks.
at 16 weeks
Secondary Endpoints
Functional status assessed using the Short Physical Performance Battery Test determined at 16 weeks. General safety and tolerability at 16 weeks.
at 16 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0822ADRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range70 Years — N/A
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Man or a woman 70 years old or older in general good health Exclusion Criteria: * Having any form of neurological impairments that may impair motor function.

Unlock Eligibility Criteria